Akcea Therapeutics, Inc. (AKCA) News
Filter AKCA News Items
AKCA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest AKCA News From Around the Web
Below are the latest news stories about Akcea Therapeutics Inc that investors may wish to consider to help them evaluate AKCA as an investment opportunity.
Akcea's Waylivra secures NICE recommendation for ultra-rare inherited disorderAkcea Therapeutics (AKCA), majority-owned affiliate of Ionis Pharmaceuticals (IONS), announces that the National Institute for Health and Care Excellence ((NICE)) has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for the treatment of Familial Chylomicronaemia Syndrome ((FCS)) for routine care on the National Health Service in England.FCS is a rare, inherited disorder characterised... |
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in EnglandLONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Evaluation Document (FED) for volanesorsen for the treatment of Familial Chylomicronaemia Syndrome (FCS) for routine care on the National Health Service (NHS) in England. FCS is an under-recognised condition characterised by extremely high triglycerides levels (10 to 100 times no |
Akcea shoots up 59% on positive vupanorsen data; Ionis acquires remaining stake for $500MAkcea Therapeutics (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals (IONS) presents data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-LRx) at the ESC Congress 2020.Vupanorsen, an investigational antisense therapy being developed using Ionis' LIgand Conjugated Antisense technology platform to reduce the production of angiopoietin-like 3 (ANGPTL3) protein from the liver which is... |
Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining StakeAkcea Therapeutics Inc (NASDAQ: AKCA ) shares were rallying strongly Monday following a buyout deal. The Ionis, Akcea Deal Terms: Akcea and its majority owner Ionis Pharmaceuticals Inc (NASDAQ: IONS ) announced a definitive agreement under which Ionis will acquire the 24% stake in Akcea it does not already own for $18.15 per share — about 60% higher than Akcea's Friday closing price. The total transaction value is about $500 million. The deal has been approved by the boards of both companies and … Full story available on Benzinga.com |
Akcea Therapeutics, Inc. 2020 Q2 - Results - Earnings Call PresentationThe following slide deck was published by Akcea Therapeutics, Inc. in conjunction with their 2020 Q2 earnings call.... |
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with PolyneuropathyAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband der Österreichischen Sozialversicherungsträger, or DV) has granted approval for the national reimbursement of TEGSEDI® (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin (hATTR) amyloidosis. |
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results WebcastAkcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress. |
Akcea Appoints New Senior Vice President, Global Medical AffairsAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice president of global medical affairs where he will lead and evolve the execution of medical strategies, activities and operations worldwide in collaboration with executive management. |
Akcea Announces Appointment of New Chief Medical OfficerAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer (CMO), effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen) and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C), will serve as an advisor to the company to ensure a smooth transition. |
Hedge Funds Keep Buying Akcea Therapeutics, Inc. (AKCA)Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […] |